ArticleJAMA2022
Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings.
Article in JAMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Prevalence of chronic respiratory disease using case-finding tools in adults living with noncommunicable disease in low- and middle-income countries: a systematic review.BMC pulmonary medicine · 2025Pooled it
- All-Cause and Cause-Specific Mortality in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Chronic Obstructive Pulmonary Disease Self-Management in Three Low- and Middle-Income Countries: A Pilot Randomized Trial.American journal of respiratory and critical care medicine · 2023Trial
- Plasma metabolomic signatures enable the diagnosis and prognosis of chronic obstructive pulmonary disease.Nature communications · 2026Article
- Physical frailty, depression and multimorbidity among older adults in Lima, Peru: a cross-sectional study.BMC geriatrics · 2026Article
- External validation of an IOS-derived model for airflow obstruction and COPD in a community-based cohort.NPJ primary care respiratory medicine · 2026Article
- Imaging in Chronic Obstructive Pulmonary Disease: Ready for Prime Time?Tuberculosis and respiratory diseases · 2026Article
- Determinants and Phenotypes of Poorly Controlled COPD Using the RADAR Score: A Cohort in Real-World Primary Care.Journal of clinical medicine · 2026Article
- Mitigating chronic respiratory disease through the lens of multimorbidity: the MARES mixed-methods study protocol.BMJ open · 2026Article
- Mobile health for chronic obstructive pulmonary disease: a bibliometric analysis based on integrated databases (2000-2025).Frontiers in medicine · 2026Review
- CAPTURE Stands Alone: Phenotypic and Endotypic Markers Add Little Value for Identification of Patients with Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2025Article
- CAPTURE and PUMA as Case-Finding Tools in Patients at Risk of COPD-A Multicenter Mexican Experience.Journal of clinical medicine · 2025Article
- Validation of artificial intelligence spirometry diagnostic support software in primary care: a blinded diagnostic accuracy study.ERJ open research · 2025Article
- Decoding Diagnostic Delay in COPD: An Integrative Analysis of Missed Opportunities, Clinical Risk Profiles, and Targeted Detection Strategies in Primary Care.Diagnostics (Basel, Switzerland) · 2025Article
- Chronic obstructive pulmonary disease screening using time-frequency features of self-recorded respiratory sounds.JAMIA open · 2025Article
- Light Convolutional Neural Network to Detect Chronic Obstructive Pulmonary Disease (COPDxNet): A Multicenter Model Development and External Validation Study.medRxiv : the preprint server for health sciences · 2025Article
- Prevalence of chronic obstructive pulmonary disease in high-risk populations at low, intermediate, high altitudes: a population based cross-sectional study in Yunnan Province, China.BMC pulmonary medicine · 2025Article
- Current status of pharmacists in community pharmacies in China in the health management of chronic respiratory diseases.BMC public health · 2025Article
- Article
- Chronic Obstructive Pulmonary Disease in People with HIV: an Evidence-Based Review.HIV/AIDS (Auckland, N.Z.) · 2025Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 8 institutions in 5 countries.
Funding
Abstract
Importance: Most of the global morbidity and mortality in chronic obstructive pulmonary disease (COPD) occurs in low- and middle-income countries (LMICs), with significant economic effects. Objective: To assess the discriminative accuracy of 3 instruments using questionnaires and peak expiratory flow (PEF) to screen for COPD in 3 LMIC settings. Design, Setting, and Participants: A cross-sectional analysis of discriminative accuracy, conducted between January 2018 and March 2020 in semiurban Bhaktapur, Nepal; urban Lima, Peru; and rural Nakaseke, Uganda, using a random age- and sex-stratified sample of the population 40 years or older. Exposures: Three screening tools, the COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE; range, 0-6; high risk indicated by a score of 5 or more or score 2-5 with low PEF [<250 L/min for females and <350 L/min for males]), the COPD in LMICs Assessment questionnaire (COLA-6; range, 0-5; high risk indicated by a score of 4 or more), and the Lung Function Questionnaire (LFQ; range, 0-25; high risk indicated by a score of 18 or less) were assessed against a reference standard diagnosis of COPD using quality-assured postbronchodilator spirometry. CAPTURE and COLA-6 include a measure of PEF. Main Outcomes and Measures: The primary outcome was discriminative accuracy of the tools in identifying COPD as measured by area under receiver operating characteristic curves (AUCs) with 95% CIs. Secondary outcomes included sensitivity, specificity, positive predictive value, and negative predictive value. Results: Among 10 709 adults who consented to participate in the study (mean age, 56.3 years (SD, 11.7); 50% female), 35% had ever smoked, and 30% were currently exposed to biomass smoke. The unweighted prevalence of COPD at the 3 sites was 18.2% (642/3534 participants) in Nepal, 2.7% (97/3550) in Peru, and 7.4% (264/3580) in Uganda. Among 1000 COPD cases, 49.3% had clinically important disease (Global Initiative for Chronic Obstructive Lung Disease classification B-D), 16.4% had severe or very severe airflow obstruction (forced expiratory volume in 1 second <50% predicted), and 95.3% of cases were previously undiagnosed. The AUC for the screening instruments ranged from 0.717 (95% CI, 0.677-0.774) for LFQ in Peru to 0.791 (95% CI, 0.770-0.809) for COLA-6 in Nepal. The sensitivity ranged from 34.8% (95% CI, 25.3%-45.2%) for COLA-6 in Nepal to 64.2% (95% CI, 60.3%-67.9%) for CAPTURE in Nepal. The mean time to administer the instruments was 7.6 minutes (SD 1.11), and data completeness was 99.5%. Conclusions and Relevance: This study demonstrated that screening instruments for COPD were feasible to administer in 3 low- and middle-income settings. Further research is needed to assess instrument performance in other low- and middle-income settings and to determine whether implementation is associated with improved clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.